CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
+7.36%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$2.52B
AUM Growth
+$2.52B
(+3.5%)
Cap. Flow
-$61.7M
Cap. Flow
% of AUM
-2.45%
Top 10 Holdings %
Top 10 Hldgs %
60.38%
Holding
42
New
11
Increased
5
Reduced
8
Closed
8
Top Buys
| 1 |
Zimmer Biomet
ZBH
|
$100M |
| 2 |
Merck
MRK
|
$77.1M |
| 3 |
Gilead Sciences
GILD
|
$64.6M |
| 4 |
Welltower
WELL
|
$58M |
| 5 |
Ventas
VTR
|
$48M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$184M |
| 2 |
Bausch Health
BHC
|
$88.4M |
| 3 |
Sarepta Therapeutics
SRPT
|
$68.2M |
| 4 |
Myriad Genetics
MYGN
|
$60.9M |
| 5 |
Biogen
BIIB
|
$49M |
Sector Composition
| 1 | Healthcare | 84.67% |
| 2 | Technology | 9.87% |
| 3 | Real Estate | 4.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CHNG
1
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $249M | 8.53% | 11,250,000 -1,750,000 | -13% | -$38.7M |
|
|
WBA
2
DELISTED
Walgreens Boots Alliance
WBA
| $206M | 7.06% | 3,750,000 +750,000 | +25% | +$41.2M |
|
3
Universal Health Services
UHS
$11.6B
| $187M | 6.41% | 1,400,000 | – | – |
|
4
Viatris
VTRS
$12.3B
| $168M | 5.75% | 12,000,000 | – | – |
|
5
Tenet Healthcare
THC
$16.3B
| $156M | 5.35% | 3,000,000 | – | – |
|
6
HCA Healthcare
HCA
$94.5B
| $146M | 5.01% | 775,000 -75,000 | -9% | -$14.1M |
|
7
Perrigo
PRGO
$3.27B
| $113M | 3.89% | 2,800,000 -200,000 | -7% | -$8.09M |
|
8
Alkermes
ALKS
$4.78B
| $105M | 3.59% | 5,600,000 -1,150,000 | -17% | -$21.5M |
|
|
9
Zimmer Biomet
ZBH
$21B
| $100M | 3.43% | +625,000 | New | +$100M |
|
|
10
Myriad Genetics
MYGN
$593M
| $91.4M | 3.13% | 3,000,000 -2,000,000 | -40% | -$60.9M |
|
11
GSK
GSK
$79.9B
| $89.2M | 3.06% | 2,500,000 -1,000,000 | -29% | -$35.7M |
|
12
Ironwood Pharmaceuticals
IRWD
$214M
| $83.9M | 2.88% | 7,500,000 | – | – |
|
|
13
Merck
MRK
$210B
| $77.1M | 2.65% | +1,000,000 | New | +$77.1M |
|
14
Brookdale Senior Living
BKD
$1.83B
| $75.6M | 2.6% | 12,500,000 +300,000 | +2% | +$1.82M |
|
|
15
Gilead Sciences
GILD
$140B
| $64.6M | 2.22% | +1,000,000 | New | +$64.6M |
|
16
Teva Pharmaceuticals
TEVA
$21.1B
| $63.5M | 2.18% | 5,500,000 +1,000,000 | +22% | +$11.5M |
|
|
17
Welltower
WELL
$113B
| $58M | 1.99% | +810,000 | New | +$58M |
|
|
18
Ventas
VTR
$30.9B
| $48M | 1.65% | +900,000 | New | +$48M |
|
19
Collegium Pharmaceutical
COLL
$1.22B
| $47.4M | 1.63% | 2,000,000 | – | – |
|
20
Ionis Pharmaceuticals
IONS
$6.79B
| $45M | 1.54% | +1,000,000 | New | +$45M |
|
21
OraSure Technologies
OSUR
$242M
| $41.7M | 1.43% | 3,575,000 +325,000 | +10% | +$3.79M |
|
22
Incyte
INCY
$16.5B
| $40.6M | 1.39% | +500,000 | New | +$40.6M |
|
23
Nektar Therapeutics
NKTR
$568M
| $40M | 1.37% | 2,000,000 -500,000 | -20% | -$10M |
|
|
RETA
24
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $39.9M | 1.37% | +400,000 | New | +$39.9M |
|
|
TECX
25
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $39.8M | 1.36% | 3,133,333 | – | – |
|